Biotech Values

[DewDiligence]

Re: JNJ/ACHN's 6-week HCV regimen

However, I think the original fibrosis/cirrhosis argument does count together with the (now unknown) performance in a more fibrotic or even cirrhotic population.

Thanks for weighing in, but I don't understand what you mean by "the original fibrosis/cirrhosis argument."

If you're saying that docs will be reluctant to treat non-cirrhotic patients who have advanced fibrosis using a regimen that hasn't been shown to work in cirrhotic patients, I agree with that.